Who owns Innate Pharma SA?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of IPHA from SEC Form 13F filings across 10 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 10 institutions disclosed 192,418 shares of Innate Pharma SA worth $354,047 — about 0.2% of shares outstanding; the largest disclosed holder is Lion Point Capital, LP. Source: SEC Form 13F filings, parsed by EvidInvest.
10
13F holders
$354,047
value, 2026 filers
0.2%
of shares outstanding (192,418 sh)
3
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of IPHA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Lion Point Capital, LP | 81,151 | $149,318 | 0.7% | 0.1% | 0.0% |
| 2 | MORGAN STANLEY | 43,524 | $80,084 | 0.0% | 0% | 0.0% |
| 3 | SmartHarvest Portfolios, LLCNEW | 23,750 | $43,700 | 0.0% | 0% | new |
| 4 | XTX Topco LtdNEW | 15,130 | $27,839 | 0.0% | 0% | new |
| 5 | CITADEL ADVISORS LLCNEW | 12,441 | $22,891 | 0.0% | 0% | new |
| 6 | JANE STREET GROUP, LLC | 10,310 | $18,971 | 0.0% | 0% | -76.2% |
| 7 | RHUMBLINE ADVISERS | 4,719 | $8,681 | 0.0% | 0% | -0.3% |
| 8 | UBS Group AG | 1,363 | $2,508 | 0.0% | 0% | +58.3% |
| 9 | Farther Finance Advisors, LLC | 21 | $38 | 0.0% | 0% | +110.0% |
| 10 | GAMMA Investing LLC | 9 | $17 | 0.0% | 0% | -96.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.